Condition: Bacterial Conjunctivitis · Sponsor: Senju USA, Inc.
This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.
This description comes directly from the study's public registry record.
Mizue Takahara · 310-935-0505 · SUM191@senju-usa.com
Satoshi Yamamoto · 310-935-0505 · SUM191@senju-usa.com
Always discuss trial participation with your own doctor first.
| Austin Clinical Research Unit | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07565103